Title: Pharmacology

Subject: Medical

Type of Paper: Literature Review

Words: 914

Systematic Literature Review On Pharmacokinetic Parameters

Burstein, Gal & Forrest (1997) conducted a study on Vancomycin Pharmacokinetics in Neonates. This study features a sparse method of sampling, prepared to provide average population pharmacokinetic data from a small number of serum samples. The theory behind this system is to get standard pharmacokinetic information from the smallest amount of samples of serum vancomycin possible devoid of introducing considerable error. According to authors, the standard technique of acquiring just two samples of vancomycin is sufficient for two-compartment modeling, when one is acquired after a 30 minutes dose and another instantaneously before a dose. Through a one-compartment model needs extending the timing of the initial vancomycin sample until 3-4 hours post-dose.

A study was conducted by Misty et al. (2011) on vancomycin dosages in children who were overweight and obese. This was a retrospective study that assessed data for 2–17 ages of children that received IV vancomycin. They were then divided into normal-weight patients and obese patients' groups. The authors were intended to compare the vancomycin regimens number between these groups with a trough concentration of 5–15 μg per mL. They were also intended to compare changes in dosage and toxicities. Multivariate, provisional logistic regression was carried out to evaluate the affiliation between receiving most favourable vancomycin concentrations (5–15 μg per mL) and autonomous variables. The authors of this study revealed no major difference in the vancomycin doses' size administered to normal-weight children than obese group. Regimens employing dosing after every eight hours were considerably more probable than other regimens to outcome in a vancomycin trough concentration of 5–15 μg per mL, and regimens for overweight group, equated with regimens for children who were non-obese, were less probable to generate trough concentrations in the identical range of 5–15 μg per mL.

Another study was performed by Giachetto et al. (2011) in which children hospitalised in the ICU and treated with vancomycin. The author obtained samples to ascertain vancomycin serum

concentration on first and third days of intervention, 1hr following the end of the third each day dose administration (maximum drug concentration) and 15mins prior to the fourth (least drug concentration). The study estimated half-life abolition, distribution volume, clearance, and area beneath the curve at 24hrs. 22 paediatric patients were participated in this study. 7 out of 18 patients for utmost drug concentration and 16 out of 22 for least drug concentration attained concentrations in therapeutic series on first day. On third day, 7 of 16 patients for utmost drug concentration and 11 of 17 for least drug concentration did. The study determined that mean values of utmost and least drug concentration were high in patients with negative balance of water. Of half-life elimination, mean value enhanced increased from first day to third day.

Literature Review On Vancomycin Dosage Guidelines For Paediatric Patients

Intravenous or IV vancomycin is approved for the infections' treatment because of Gram-positive bacteria, according to Lisby-Sutch & Nahata (1988). Most of the hospitals use this for the treatment of penicillin defiant pneumococcal meniningitis, methicillin-resistant Staphylococcus aureus, and septicaemia because of vulnerable organisms (Lisby-Sutch & Nahata, 1988). In accordance with Bartelink et al. (2006), principally vancomycin is eliminated through kidneys and reduction in dose is essential in the renal impairment presence. Levels are taken to make sure therapeutic concentrations are attained.

A loading dose of 15mg per kg is recommended by is recommended by Rybak et al. (2009) in 1 month to 18 years of paediatric patients, followed by a 10mg per kg qds dosage treatment, not more than 2g per day (Carol et al. 2007). On the other hand, the recommended dose of BNF-C is 15mg per kg tds regimen without loading dose (Frymoyer et al. 2009). Moreover, some healthcare centres have set their own guiding principles. These discrepancies have led to some ambiguity in trusts, as no standard guiding norms exists for intravenous vancomycin.

The BNF for children altered their range of target from 5 to10 mg per l to 10 to 15 mg per l secondary to suggestions from the Special Advisory Committee on Antimicrobial Resistance (McCaffery & Sinclair, 2006). The dosing plan of 15 mg per kg on every 8 hours did not alter. The main aim of this study was to develop whether levels were therapeutic in accordance with the dosing in the BNFc. However, in this study more than 70% of all levels in vancomycin taken were sub therapeutic employing the present BNFc dosing treatment. This study highlighted that the BNFc dosing treatment is unsuccessful at producing adequate levels of vancomycin. (McCaffery & Sinclair, 2006)

Achieving Target Concentrations

Least serum vancomycin trough concentrations should be maintained at all times above 10 mg per L to stay away from resistance development. For an infectious agent with an MIC of 1 mg per L, the least trough concentration would have to be minimum 15 mg per L to produce the target AUC: MIC of 400. The most precise and practical technique to monitor vancomycin effectiveness are trough serum vancomycin concentrations. It should be obtained just prior to the next dose at steady state situations (Evidence level = II, grade of suggestion = B).

Evidence recommends that S. aureus revelation to trough serum vancomycin concentrations of <10 mg per L can generate strains with VISAlike features, it is suggested that trough serum vancomycin concentrations constantly be sustained above 10 mg per L to keep away from resistance development (Evidence level = III, grade of suggestion = B).

REFERENCES

- Bartelink, I. H., Rademaker, C. M., Schobben, A. F., & van den Anker, J. N. (2006). Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. *Clinical pharmacokinetics*,*45*(11), 1077-1097.
- Burstein AH, Gal P, Forrest A. (1997). Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: Application of optimal sampling theory. *Ann Pharmacother* ;31:980-3.
- Carol K. Taketomo, Jane Hurlburt Hodding, Donna M. Kraus. (2007). *Pediatric Dosage Handbook*. Publisher Lexi-Comp.
- Frymoyer A et al. (2009). Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections is Inadequate. *Ped Infect Dis J*; 28(5):398-402.
- Giachetto GA. et al. (2011). Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. *Pediatr Crit Care Med*. 12(6):e250-4.
- Lisby-Sutch, S. M., & Nahata, M. C. (1988). Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. *European journal of clinical pharmacology*, *35*(6), 637-642.
- McCaffery, K., & Sinclair, J. (2006). Special considerations in paediatric intensive care. *Anaesthesia & Intensive Care Medicine*, *7*(1), 22-28.

- Misty Miller, Jamie L. Miller, Tracy M. Hagemann, Donald Harrison, Susana Chavez-Bueno, Peter N. Johnson. (2011). Vancomycin Dosage in Overweight and Obese Children. *Am J Health Syst Pharm*.68(21):2062-2068.
- Rybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., ... & Levine, D. P. (2009). Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. *Clinical infectious diseases*, *49*(3), 325-327.
- Wrishko, R. E., Levine, M., Khoo, D., Abbott, P., & Hamilton, D. (2000). Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.*Therapeutic drug monitoring*, *22*(5), 522-531.